Abstracts de nos Amis Espagnols au WCLC

 

 

  [P2.06] Poster Session 2 – Prognostic and Predictive Biomarkers
Tuesday, October 29, 2013
9:30 AM – 4:30 PM  Exhibit Hall, Ground Level
Impact of EGFR T790M mutations and BIM mRNA expression on progression-free survival (PFS) and overall survival (OS) in patients with EGFR-mutant non-small-cell lung cancer (NSCLC) treated with erlotinib or chemotherapy in the randomized phase III EURTAC

[pdf]Impact of EGFR T790M….[/pdf]


[O15.02] Oral Abstract Session – NSCLC – Chemotherapy II
 Tuesday, October 29, 2013
 10:30 AM – 12:00 PM   Bayside Auditorium A, Level 1

The Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor (EGFR) (NCT00617)

[pdf]O15.02 The SLCG BRCA1-RAP80…[/pdf]


 

Mini Oral Abstract Session, [MO21] Prognostic and Predictive Biomarkers V – EGFR
Wed, October 30, 2013
10:30 AM – 12:00 PM  Bayside Auditorium A, Level 1

Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer (NSCLC) patients with acquired resistance to erlotinib.
[pdf] MO21.05 Integrated genomic analysis …[/pdf]


 

 Mini Oral Abstract Session, [MO26] Anatomical Pathology II
Wed, October 30, 2013
 10:30 AM – 12:00 PM   Bayside 105, Level 1

The concomitant presence of echinoderm microtubule associated protein like 4 – anaplastic lymphoma kinase (EML4-ALK) EML4-ALK fusion gene in EGFR-mutant non-small-cell lung cancer (NSCLC) patients treated with erlotinib or chemotherapy in the EURTAC trial
[pdf]MO26.08 The concomitant presence….EURTAC Trial[/pdf]


 

 Poster Session, [P3.02-009] Poster Session 3 – Novel Cancer Genes and Pathways
Wed, October 30, 2013
 9:30 AM – 4:30 PM Exhibit Hall, Ground Level

ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer (NSCLC) patients with the EGFR T790M mutation

[pdf] P3.02-009 ROR1 as a novel therapeutic….[/pdf]